Search Results

Edwards Lifesciences announced it has entered into a definitive agreement to sell its Critical Care product group to BD, in an all-cash transaction valued at $4.2 billion.

Edwards Lifesciences reported financial results for the quarter ended March 31, 2024.

Edwards Lifesciences reported financial results for the quarter ended December 31, 2023.

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.

Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

BD, a leading global medical technology company, and Edwards Lifesciences, announced a definitive agreement under which BD will acquire Edwards’ Critical Care product group, a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD’s portfolio of smart connected care solutions.